Panama

The primary regulatory authority for health products in Panama is the Direccion Nacional de Farmacia y Drogas (DNFD), operating under the Ministerio de Salud (MINSA). The legal framework is anchored in Law 1 of 2001 and its implementing regulations, which govern the registration, importation, commercialization, and post-market surveillance of pharmaceuticals, medical devices, diagnostics, and related health products. All health products must obtain a Registro Sanitario (sanitary registration) before they may be legally marketed or procured in the country. The DNFD evaluates applications through a structured dossier review process, with expedited pathways available for products already approved by stringent regulatory authorities such as the US FDA, EMA, or Health Canada, which can meaningfully shorten review timelines.

Applicants are required to appoint a local legal representative or authorized distributor registered in Panama to submit and manage dossier applications on behalf of foreign manufacturers. Technical dossiers are generally expected to follow the Common Technical Document (CTD) format, and supporting documentation must be submitted in Spanish or accompanied by certified translations. Panama increasingly accepts reference country approvals as part of its abridged or expedited review procedures, reducing the evidentiary burden for products with established international safety and efficacy profiles. In recent years, MINSA and the DNFD have undertaken digital transformation initiatives aimed at streamlining the registration process, reducing administrative backlogs, and aligning more closely with regional harmonization efforts led by PANDRH (Pan American Network for Drug Regulatory Harmonization), reflecting a broader commitment to modernizing the regulatory ecosystem.

Public procurement of health products in Panama is primarily coordinated through the Caja de Seguro Social (CSS), the national social security system, and MINSA, which together cover the majority of the population and represent the largest institutional buyers of pharmaceuticals, medical devices, and diagnostics. Tenders are governed by Law 22 of 2006 on public contracting and administered through the national electronic procurement platform, PanamaCompra, which requires all public institutions to publish and award contracts transparently. The CSS and MINSA conduct separate procurement processes, with the CSS managing a substantial independent formulary and supply chain for its beneficiary population, while MINSA focuses on public health programs, primary care facilities, and underserved communities. Joint or coordinated purchasing between the two institutions occurs periodically to achieve economies of scale, and suppliers must hold a valid Registro Sanitario and meet local regulatory requirements to participate in public tenders.

The private sector constitutes a significant and growing channel for health product commercialization in Panama, particularly in Panama City, where a well-developed network of private hospitals, clinics, pharmacies, and specialty distributors operates. Private procurement follows commercial contracting norms and is not subject to the same tendering requirements as public institutions, offering manufacturers more flexible market entry pathways. Panama also serves as a regional hub for international organizations and donor-funded health initiatives, with entities such as PAHO/WHO, UNICEF, and USAID maintaining regional offices or programs that influence procurement standards and product selection. While Panama does not have a formal local manufacturing preference policy equivalent to those seen in some larger Latin American markets, domestic production capacity is limited, and the country relies heavily on imported health products, making regulatory efficiency and distributor relationships critical factors for successful market access.